title: Assessment of a selective inhibitor of herpes simplex virus thymidine kinase (L-653,180) as therapy for experimental recurrent genital herpes.
abstract: Herpes simplex virus (HSV)-coded thymidine kinase (TK) is important in efficient reactivation of latent infection. These studies were designed to investigate whether treatment of latently infected animals with a TK inhibitor altered the natural history of recurrent HSV disease. 9-([(Z)-2-(hydroxymethyl)cyclohexyl]methyl) guanine (L-653,180) is a potent and selective nonsubstrate inhibitor of HSV TK which can suppress or delay reactivation of HSV-1 from latently infected cells in vitro without affecting viral replication. In an initial study, six female Hartley guinea pigs were treated with L-653,180 in their diet (25 mg/30 g of food) and water (300 mg/liter) for 7 days. Blood, urine, kidney, liver, spinal cord, and cerebral cortex specimens were collected. L-653,180 was detected in all specimens at concentrations which, although low, were higher than the in vitro 50% inhibitory concentration of the drug against HSV TK. In the second study, 20 female Hartley guinea pigs were randomized into two groups following recovery from primary genital HSV-2 infection. One group received L-653,180 in diet and water for 4 weeks beginning 21 days postinoculation. Animals were examined daily for recurrent lesions for 10 weeks. Treated animals experienced fewer recurrences during the treatment period but the results were not significantly different from results with controls. During the first 2-week posttreatment period, L-653,180-treated animals had significantly fewer recurrences than control animals (P = 0.02). Over the entire 10-week observation period, treated animals experienced fewer recurrences (P = 0.06). These results suggest that inhibitors of viral TK may be useful in limiting reactivation of latent virus and thus recurrent infections. In these experiments, the amount of drug that could be administered to the animals was limited by its poor solubility. Further studies with more potent and soluble inhibitors of HSV TK appear to be warranted.
authors.affiliation: Children's Hospital Research Foundation, Department of Pediatrics, University of Cincinnati College of Medicine, Ohio 45229, USA.
authors.forename: N
authors.initials: N
authors.lastname: Bourne
authors.forename: F J
authors.initials: FJ
authors.lastname: Bravo
authors.forename: W T
authors.initials: WT
authors.lastname: Ashton
authors.forename: L C
authors.initials: LC
authors.lastname: Meurer
authors.forename: R L
authors.initials: RL
authors.lastname: Tolman
authors.forename: J D
authors.initials: JD
authors.lastname: Karkas
authors.forename: L R
authors.initials: LR
authors.lastname: Stanberry
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006168:Guinea Pigs; D006558:Herpes Genitalis / Q000188:drug therapy*; D012008:Recurrence; D018139:Simplexvirus / Q000201:enzymology*; D013937:Thymidine Kinase / Q000037:antagonists & inhibitors*
chemical_list: D000998:Antiviral Agents; C065860:9-((2-(hydroxymethyl)cyclohexyl)methyl)guanine; D006147:Guanine; D013937:Thymidine Kinase